Report copyright - Q2 2013 RESULTS - Sanofi · When including Brazil generics , Emerging Markets sales were down -2.3% at CER in Q2 2013 and up +1.9% in H1 2013 (3) Genzyme perimeter includes Rare Diseases
Please pass captcha verification before submit form